readthroughSign in
CompanyKRRONasdaqCambridge, MA

Korro Bio, Inc.

Korro Bio develops RNA-editing oligonucleotides using its OPERA platform to modify native mRNA transcripts for rare and prevalent diseases.

SCHEDULE 13G/ANov 16Latest SEC filing
Nov 5Latest story